Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies
JMIR Research Protocols · 2025
DOI: 10.2196/77836 ↗At a glance
Studienprotokoll in JMIR Research Protocols, 2025. Written by Nana A Mensah and 12 co-authors. Institution: Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Major MEDLINE topics: Erythroblastosis, Fetal. 32 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Hemolytic disease of the fetus and newborn (HDFN) is a rare but serious condition caused by maternal-fetal red blood cell antigen incompatibility. In an affected pregnancy, maternal immunoglobulin G antibodies cross the placenta and target fetal or neonatal red blood cells, leading to hemolysis, hyperbilirubinemia, and anemia. Although routine screening and alloimmunization prevention programs have contributed to the decline in HDFN in the United States, further understanding of its epidemiology is still needed.
Objective
This protocol aims to provide an overview of the study design, methodology, and analytical approach used to investigate the epidemiology, treatment, and health care resource use of HDFN within a large integrated health care system.
Methods
We conducted a retrospective cohort study of pregnant women who received obstetric care in the Kaiser Permanente Southern California (KPSC) health care system from January 1, 2008, to June 30, 2022. To identify HDFN cases, we used a novel methodology developed by KPSC researchers combining structured data and detailed clinical information extracted from unstructured records via a natural language processing–assisted chart review process. Chi-square and Wilcoxon rank sum tests were used to compare the distributions of maternal and infant demographic characteristics, as well as medical and perinatal conditions, by HDFN status. We also evaluated the association between HDFN and adverse perinatal outcomes using logistic regression models. Planned analyses using this unique cohort will include describing the annual prevalence, health care resource use, and treatment patterns of mothers and infants by HDFN status.
Results
The study population consisted of 464,711 pregnancies, of which 136 (0.03%) were HDFN cases confirmed by chart review, resulting in 138 (0.03%) births (n=137, 0.99% live births and n=1, 0.01% stillbirth). The mean age at pregnancy was 29.8 (SD 5.7) years, and the population was racially and ethnically diverse.
Conclusions
We present an overview of the methodology developed by KPSC clinicians and researchers on the epidemiology, treatment, and health care resource use of HDFN within a large and demographically diverse population of pregnant women. Our novel methodology, combining both structured and unstructured data and a natural language processing–assisted chart review process, ensures the successful identification of true cases to carry out pharmaco-epidemiological studies. International Registered Report Identifier (IRRID) DERR1-10.2196/77836
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States.
- Department of Obstetrics & Gynecology, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, CA, United States.
- Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States.
- Johnson & Johnson, Horsham, PA, United States.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, United States.
ORCID profiles: Nana A Mensah, Michael J Fassett, Nehaa Khadka, Jiaxiao M Shi, Fagen Xie, Vicki Y Chiu, Theresa M Im, Sunhea Kim, Daniella Park, Carol Mao, Matthew Molaei, Iris Lin, Darios Getahun
Cite
APA
Mensah, N. A., Fassett, M. J., Khadka, N., Shi, J. M., Xie, F., Chiu, V. Y., Im, T. M., Kim, S., Park, D., Mao, C., Molaei, M., Lin, I., & Getahun, D. (2025). Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies. JMIR Research Protocols. https://doi.org/10.2196/77836
Vancouver
Mensah NA, Fassett MJ, Khadka N, Shi JM, Xie F, Chiu VY, et al. Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies. JMIR Research Protocols. 2025. doi:10.2196/77836
BibTeX
@article{Mensah2025,
author = {Mensah, Nana A and Fassett, Michael J and Khadka, Nehaa and Shi, Jiaxiao M and Xie, Fagen and Chiu, Vicki Y and Im, Theresa M and Kim, Sunhea and Park, Daniella and Mao, Carol and Molaei, Matthew and Lin, Iris and Getahun, Darios},
title = {Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies},
journal = {JMIR Research Protocols},
year = {2025},
doi = {10.2196/77836}
}
EUVIMED